The FDA cleared the investigational new drug application for MRANK-106, a dual WEE1/YES1 kinase inhibitor, targeting advanced ...
These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They ...
Based on extensive preclinical studies, MRANK-106 is differentiated from other WEE1 inhibitors in development by its: Dual targeting of WEE1 and YES1 kinases, providing synergistic anti-tumor effects ...
The biotech company Dynamic42, a specialist in organ-on-chip technology, has made a significant advance in pancreatic cancer ...
Dr. Marty Makary, President Trump's pick to run the Food and Drug Administration, faced questions from the Senate HELP ...
Medical Device Network on MSN3d
Tumour-on-chip model could help discover pancreatic cancer therapiesProfessor Teusch and Dynamic42 set out their work in one of the most challenging cancers, with PDAC being the most common and lethal form of pancreatic cancer. A major cause of it ...
Dr. Marty Makary will testify before the Senate health committee on Thursday. Lawmakers may press him over staff reductions ...
The statement unites the cancer community in opposing recent executive actions and calling on both the administration and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback